company background image
CGEN logo

Compugen TASE:CGEN Stock Report

Last Price

₪8.20

Market Cap

₪715.7m

7D

8.5%

1Y

17.5%

Updated

21 Jan, 2025

Data

Company Financials +

Compugen Ltd.

TASE:CGEN Stock Report

Market Cap: ₪715.7m

CGEN Stock Overview

A clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. More details

CGEN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Rewards

Became profitable this year

Risk Analysis

Earnings are forecast to decline by an average of 43.4% per year for the next 3 years

Volatile share price over the past 3 months compared to the IL market


My Notes

Capture your thoughts, links and company narrative

Compugen Ltd. Competitors

Kamada

TASE:KMDA

₪1.5b

G.F.C Green Fields Capital

TASE:GFC-M

₪115.4m

TOT BIOPHARM International

SEHK:1875

HK$1.3b

Santhera Pharmaceuticals Holding

SWX:SANN

CHF 189.0m

Price History & Performance

Summary of share price highs, lows and changes for Compugen
Historical stock prices
Current Share PriceUS$8.20
52 Week HighUS$11.75
52 Week LowUS$5.12
Beta2.59
1 Month Change46.40%
3 Month Change30.64%
1 Year Change17.51%
3 Year Change-24.84%
5 Year Change-67.30%
Change since IPO0%

Recent News & Updates

Recent updates

Shareholder Returns

CGENIL BiotechsIL Market
7D8.5%-3.5%2.4%
1Y17.5%-20.7%35.7%

Return vs Industry: CGEN exceeded the IL Biotechs industry which returned -21.6% over the past year.

Return vs Market: CGEN underperformed the IL Market which returned 34% over the past year.

Price Volatility

Is CGEN's price volatile compared to industry and market?
CGEN volatility
CGEN Average Weekly Movement8.5%
Biotechs Industry Average Movement10.5%
Market Average Movement4.4%
10% most volatile stocks in IL Market9.1%
10% least volatile stocks in IL Market3.1%

Stable Share Price: CGEN's share price has been volatile over the past 3 months compared to the IL market.

Volatility Over Time: CGEN's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of IL stocks.

About the Company

FoundedEmployeesCEOWebsite
199368Anat Cohen-Dayagcgen.com

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18.

Compugen Ltd. Fundamentals Summary

How do Compugen's earnings and revenue compare to its market cap?
CGEN fundamental statistics
Market cap₪715.68m
Earnings (TTM)₪5.68m
Revenue (TTM)₪212.62m

126.0x

P/E Ratio

3.4x

P/S Ratio

Is CGEN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CGEN income statement (TTM)
RevenueUS$59.85m
Cost of RevenueUS$9.26m
Gross ProfitUS$50.59m
Other ExpensesUS$48.99m
EarningsUS$1.60m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.018
Gross Margin84.53%
Net Profit Margin2.67%
Debt/Equity Ratio0%

How did CGEN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/21 13:52
End of Day Share Price 2025/01/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Compugen Ltd. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Varun KumarCantor Fitzgerald & Co.
Ling WangChardan Capital Markets, LLC
Vernon BernardinoFBR Capital Markets & Co.